Breaking News from #EASD2018


This page was last updated at 03:13 p.m. PT Oct 05, 2018.

Editor’s Note: This article will be updated regularly with breaking news and announcements during the course of the European Association for the Study of Diabetes Conference. Check back often! Follow along on twitter at #EASD2018.

Monday, October 1st

Tuesday, October 2nd

  • PIONEER 1 trial indicated that, in comparison with placebo, once-daily oral semaglutide was associated with significant reductions in HbA1c, weight and both in adults with type 2 diabetes.
  • Professor Jaakko Tuomilehto “Early weight loss predicts greater type 2 diabetes prevention effect” lifestyle early interventions seem to have predictive success.
  • Roche and Novo Nordisk will work together to integrate insulin dosage information from Novo Nordisk’s connected pen technology into Roche’s open ecosystem, communicating with its digital diabetes management solutions including mySugr, according to Press Release.
  • New European Diabetes Forum launched to drive policy the European Association for the Study of Diabetes (EASD) has announced the launch of a new coalition, the European Diabetes Forum (EUDF). The Forum’s Call to Action sets out the identified causes in European healthcare systems of the failure in managing a chronic, complex and growing disease like diabetes, as well as potential solutions to address them.

Thursday, October 4th

  • New research shows that after age 30, people with type 1 diabetes are frequently not identified and often misdiagnosed as having type 2 diabetes. The study was conducted by Dr. Nick Thomas, who stated, “the majority of patients needing insulin within three years of diagnosis will have type 1 diabetes, even if they were initially thought to have type 2 diabetes.”